SIMULTANEOUS ESTIMATION OF UMIFERNOVIR AND FAVIRAPREVIR IN TABLET DOSAGE FORMS BY RP-HPLC

The development and validation of a liquid chromatographic method ingradient mode for Simultaneous Quantification of Faviraprevir and Umifernovir in tablet dosage forms by Isocratic RP-HPLC Method. For assessing Umifernovir and Faviraprevir whole sale pharmaceuticals and pharmaceutical solutions, the study presents a sensitive, accurate, and accurate Opposite Phase HPLC method. The retention durations for Umifernovir and Faviraprevir were 6.905 minutes for Umifernovir and 2.736 minutes for Faviraprevir. The most effective blend for achieving well-defined and tailing-free heights was found to be 0.1 percent (v/v) (TFA): CH3OH in a 10:90 v/v proportion. The newly designed HPLC method required less time for reference criterion preparation and did not require any time-consuming removal. Between the concentration series of calibration zone of 20-240mcg-mL-1, each of Umifernovir and Faviraprevir, a fairly-linear correlation (r2=0.999) was found. Reduced standard deviation figures indicate that the procedure is highly accurate. The assay outcomes for Umifernovir and Faviraprevir tablet computers were98.8 % and 98.9 percent, respectively. According to the healing trials, about 99.2 % of Umifernovir and 100.2 percent of Faviraprevir were recovered, indicating that the technique was highly precise. This indicates established LC method-technique is simple, linear, precise, delicate, and repeatable